Valeant in talks to buy Actavis for over $13 billion: WSJ
(Reuters) - Canada's biggest listed drug maker, Valeant Pharmaceuticals International Inc (VRX.TO), is in talks to buy generic drugmaker Actavis Inc (ACT.N) for more than $13 billion, Wall Street Journal reported, citing people familiar with the matter.
The companies had been working towards an all-stock deal, when some of Actavis' directors came out against it around the middle of this week. But executives on the two sides are still working to resurrect the deal, the journal said.
Valeant said in February it was in talks to make more acquisitions, and it remains open to discuss a potential "merger of equals."
Shares of Actavis, which has a market capitalization of $12.9 billion, have risen about 12 percent in the past three months.
Actavis, the third-largest global generic drugmaker, changed its name in January from Watson after buying Actavis as part of its strategy to expand in international markets and offer more specialty drugs.
Valeant and Actavis could not be immediately reached for comments outside of business hours.
(Reporting by Neha Alawadhi in Bangalore; Editing by Bernard Orr)
NEW YORK - U.S. stocks edged modestly lower on Monday, and the S&P 500 held near record highs, as investors largely shrugged off unexpectedly weak data in China. | Video
- U.S. small businesses borrowed more money in January than they did a year earlier, signaling continued growth in the economy despite a spate of cold weather that has been blamed for weakness in many other indicators of activity.
BEIJING/HONG KONG - China reiterated its opposition on Thursday to a European Union plan to limit airline carbon dioxide emissions and called for talks to resolve the issue a day after its major airlines refused to pay any carbon costs under the new law.